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Abstract
Haloperidol, a classical antipsychotic drug, affects the extracellular signal-regulated kinase (ERK)
pathway in the brain. However, findings are inconsistent and the mechanism by which haloperidol
regulates ERK is poorly understood. Therefore, we examined the ERK pathway and the related protein
phosphatase 2A (PP2A) in detail after haloperidol administration. Haloperidol (0.5 and 1 mg/kg) induced
biphasic changes in the phosphorylation level of mitogen-activated protein kinase kinase (MEK), ERK,
and p90 ribosomal S6 kinase (p90RSK) without changing Raf-1 phosphorylation. Fifteen minutes
after haloperidol administration, MEK-ERK-p90RSK phosphorylation increased, whilst PP2A activity
decreased. At 60 min, the reverse was observed and the binding of PP2A to MEK and ERK increased.
Higher dosages of haloperidol (2 and 4 mg/kg), affected neither MEK-ERK-p90RSK phosphorylation
nor PP2A activity. Accordingly, PP2A regulates acute dose- and time-dependent changes in MEK-
ERK-p90RSK phosphorylation after haloperidol treatment. These findings suggest the involvement of a
dephosphorylating mechanism in the acute action of haloperidol.
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Introduction
Haloperidol is a classical antipsychotic drug used to
treat an array of psychotic disorders. Traditionally, the
clinical potency of antipsychotics was thought to be
related to its capacity to antagonize the dopamine D2
receptor (Creese et al., 1976). Whilst the inhibitory ef-
fect on the receptor is instantaneous, its antipsychotic
effect requires chronic treatment-inducing long-term
adaptive changes (Meltzer, 1991), which are mediated
via intracellular signalling pathways. Acute regulation
of signalling pathways by antipsychotics is an im-
portant first step in inducing a chronic response,
which includes changes in gene expression (Li et al.,
2007). Therefore, understanding the acute effect of
antipsychotics on the intracellular signalling cascades
is important.
The extracellular signal-regulated kinase (ERK)
signal pathway is thought to be involved in the
mechanism of antipsychotics and psychotomimetics
(Ahn et al., 2006 ; Beaulieu et al., 2006 ; Pozzi et al.,
2003 ; Valjent et al., 2004). ERK participates in a variety
of neuronal functions, including the regulation of
gene expression, protein synthesis, and receptor
modulation, which contribute to synaptic plasticity
and adaptive behaviours such as learning and mem-
ory (Sweatt, 2004).
The acute effect of haloperidol, a D2 receptor an-
tagonist, on ERK activity has also been investigated.
However, findings on the relationship between the D2
receptor and the ERK pathway are mixed. Stimulation
of the D2 receptor inhibited ERK phosphorylation in
pituitary and striatal cell cultures (Banihashemi and
Albert, 2002 ; Liu et al., 2002 ; Van-Ham et al., 2007),
and haloperidol acutely up-regulated ERK phosphor-
ylation in the striatum and frontal cortex of rodents
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(Pozzi et al., 2003 ; Valjent et al., 2004) and in cell
lines (Yang et al., 2004). In contrast, activation of the
D2 receptor was also reported to increase ERK phos-
phorylation in vitro and in vivo (Cai et al., 2000;
Wang et al., 2005) with ERK phosphorylation accord-
ingly found to be reduced in mouse and rat prefrontal
cortex after a single treatment with haloperidol
(Fumagalli et al., 2006 ; Pascoli et al., 2005). These
contradictory findings could have resulted from dif-
ferent experimental conditions such as the kind or
dose of receptor-modulating agents and the duration
of treatments. The reports concerning the effect of
haloperidol on the ERK pathway also examined a
limited range of haloperidol doses and time-points.
Moreover, the regulators of the ERK pathway in
response to haloperidol treatment remain to be ex-
amined. Therefore, we investigated the ERK pathway
in more detail and the molecules regulating ERK
following haloperidol treatment.
The phosphorylation of ERK is regulated by
interplay between kinases and phosphatases. Raf-1,
recruited by GTP-bound Ras, is the best-known up-
stream kinase activating the mitogen-activated protein
kinase kinase (MEK)-ERK pathway. Phosphorylation
of its Ser338 residue activates Raf-1, whilst hyper-
phosphorylation of Ser259 interferes with its activity
(Baccarini, 2005). In addition, several phosphatases
have been reported to regulate ERK phosphorylation
in the brain, including protein serine/threonine phos-
phatase PP2A, mitogen-activated protein kinase
phosphatase (MKP)MKP-1/2 andMKP-3, and protein
tyrosine phosphatases (PTP) haematopoietic PTP
(HePTP), striatal enriched PTP (STEP), and PTP-SL
(Murphy and Blenis, 2006). Of these, protein phos-
phatase 2A (PP2A) has been suggested to be one of
the key regulators of MEK-ERK phosphorylation in
the brain (Mao et al., 2005 ; Pei et al., 2003). PP2A
negatively regulates ERK activity through the dephos-
phorylation of MEK or ERK, whilst PP2A can
also positively regulate ERK activity via dephos-
phorylation of inhibitory upstream kinases of ERK,
such as Ser259-Raf-1 (Adams et al., 2005 ; Alessi et al.,
1995 ; Sontag, 2001). Therefore, the effect of PP2A on
ERK activity is determined by the interacting partner
within the Ras-Raf-MEK-ERK signalling pathway.
We hypothesized that the changes in ERK phos-
phorylation could be time- and dose-dependent
and dephosphorylating action could be involved in
regulating ERK phosphorylation in response to
haloperidol treatment. Based on this hypothesis, we
examined the time- and dose-dependent changes in
ERK phosphorylation in detail, as well as those of
molecules upstream (Raf-1 andMEK) and downstream
[p90 ribosomal S6 kinase (p90RSK)] from ERK in
the rat frontal cortex, a suggested site for the common
action of diverse antipsychotics (MacDonald et al.,
2005). In addition, to examine the involvement of
phosphatase in ERK regulation after haloperidol treat-
ment, PP2A activity and the binding of PP2A to Raf-1,
MEK, or ERK were examined.
Method
Animals and drug treatment
Male Sprague–Dawley rats (150–200 g) were grouped
and maintained on a 12-h light–dark cycle with food
andwater freely available. The animals were treated in
accordance with the NIH Guide for the Care and Use
of Laboratory Animals. Haloperidol (Sigma-Aldrich,
Steinheim, Germany) 0.5, 1, 2, and 4 mg/kg dissolved
with 0.3% tartaric acid and pH adjusted to 6.0
was injected into the rats intraperitoneally, whilst
control animals received an equivalent volume of
0.3% tartaric acid at the same pH.
To examine the temporal pattern of changes, we
observed the phosphorylation level 15, 30, 60, and
120 min after haloperidol treatment. Four animals
were assigned to each treatment group (vehicle, 0.5, 1,
2, or 4 mg/kg haloperidol for each time-point) for
immunoblot analysis. For selected treatment groups
based on the immunoblot results, 3–5 different rats
were used for PP2A activity assay, immunoprecipi-
tation, and Raf-1 kinase activity assay.
Immunoblot analysis
Whole extracts of frontal cortex were used for im-
munoblot analysis. Frontal cortices were immediately
homogenized in a glass–Teflon homogenizer in 10%
v/w ice-cold RIPA(+) buffer [50 mM Tris (pH 7.4),
150 mM NaCl, 1% Triton, 1% sodium deoxycholate,
and 0.1% SDS] containing 1 mM DTT, protease inhibi-
tor cocktail (Sigma–Aldrich), and 1 mM PMSF (Sigma-
Aldrich). Subsequent steps for immunoblot analysis
was performed as described previously (Ahn et al.,
2006). Antibodies against actin (Sigma-Aldrich), Raf-1,
MEK1/2, ERK1/2, p90RSK, PP2A catalytic subunit
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
phospho-Raf-1 (Ser259 or Ser338), phospho-MEK1/2
(Ser217/221), phospho-ERK1/2 (Thr202/Tyr204), or
phospho-p90RSK (Thr360/Ser364) (Cell Signaling
Technology, Beverly, MA, USA) were used as primary
antibodies at dilutions of 1 :1000 to 3000. They were
incubated overnight at 4 xC, and this was followed by
a second incubation with anti-rabbit IgG conjugated to
horseradish peroxidase (Santa Cruz Biotechnology).
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The signal was detected with the ECL system (Pierce,
Rockford, IL, USA).
Immunoprecipitation
Tissues were homogenized in RIPA buffer [50 mM
Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5%
deoxycholate, 1 mM EGTA, 1 mM EDTA, and protease
inhibitor cocktail (Sigma-Aldrich)], and 1 mM PMSF
(Sigma-Aldrich). After pelleting the insoluble proteins
at 20 000 g for 20 min, the supernatant was pre-cleared
with protein A-agarose. The pre-cleared samples
were immunoprecipitated overnight with antibodies
against Raf-1, MEK1/2 or ERK1/2 antibody. The im-
munocomplexes were recovered using protein A- or
G-agarose and analysed by immunoblotting using
antibodies against PP2A, Raf-1, MEK1/2, or ERK1/2.
The ratios of immunoreactivity of PP2A to that of
Raf-1, MEK, or ERK in the immunoprecipitated
samples were compared as described in the Statistical
analysis section.
Serine and threonine phosphatase assay
PP2A activity was determined using a molybdate dye-
based phosphatase assay kit (cat. no. V2460, Promega,
Madison, WI, USA). We described the detailed pro-
cedure in a previous report (Kang et al., 2005). In
addition, the specificity of the PP2A activity was
evaluated via collateral assays using okadaic acid
(OA; 1 and 5 mM) as a PP2A inhibitor. OA inhibits PP1
as well as PP2A (Suganuma et al., 1992). However,
since the substrate in this kit, RRA(pT)VA, is a poor
substrate for PP1, it can be presumed that the OA-
sensitive measured activity originated from PP2A. The
optical densities (ODs) of the samples were assessed
using a plate reader fitted with a 630-nm filter.
Raf kinase activity assay
Raf-1 kinase activity was determined using a Raf-1
kinase assay kit (cat. no. 17-360, Upstate Biotechnology,
Lake Placid, NY, USA) according to themanufacturer’s
instructions. Briefly, tissue extracts were incubated
with a Mg/ATP cocktail, inactive MEK1/2 substrate,
and assay dilution buffer I for 30 min at 30 xC and
then boiled with Laemmli’s sample buffer. Phospho-
MEK1/2 in the reaction was detected by immunoblot
analysis with anti-phospho-MEK1/2 antibody.
Statistical analysis
The results are expressed as relative ODs, which are
the percentages of the ODs compared to vehicle
values, and are reported as the mean¡S.E. The mean
relative OD from the immunoblot analysis or phos-
phatase assay and the ratios of immunoreactivity from
the immunoprecipitation analysis were compared
using one-way analysis of variance (ANOVA) or two-
way ANOVA considering the effect of dosage and
time, and pairwise comparisons were performed using
Tukey’s post-hoc test. p values<0.05 were considered
statistically significant. All tests were performed using
SPSS 12.0 for Windows (SPSS, Chicago, IL, USA).
Results
Haloperidol affected the phosphorylation state of
MEK1/2, ERK1/2, and p90RSK in the rat frontal
cortex in a dose- and time-dependent manner.
Haloperidol (0.5 and 1 mg/kg) transiently increased
the immunoreactivities of p-Ser217/221-MEK1/2,
p-Thr202/Tyr204-ERK1/2, and p-Thr360/Ser364-
p90RSK at 15 min (all p<0.05), and then decreased
all of them below the vehicle control value from
30 min to 120 min after the treatment (all p<0.05).
Higher doses (2 and 4 mg/kg) did not induce signifi-
cant changes in the phosphorylation level of any
molecule examined at any time. No changes occurred
in the immunoreactivities of total MEK1/2, ERK1/2,
and p90RSK at any dosage until 120 min. The im-
munoreactivities of p-Ser338-Raf-1 and p-Ser259-
Raf-1, a canonical upstream kinase of MEK, did not
change significantly under any condition examined.
The immunoreactivity of total Raf-1 also did not
change (Figure 1).
A transient increase in phosphorylation followed
by a long-lasting decrease suggested activation of an
active dephosphorylating mechanism. Therefore, we
examined the activity of PP2A after haloperidol treat-
ment in the rat frontal cortex. The activity was ex-
amined 15 min and 60 min after 0.5 or 2 mg/kg
haloperidol treatment. The doses and times were
selected based on the phosphorylation data reported
above. At the lower dose (0.5 mg/kg), PP2A activity
was reduced significantly compared to the vehicle
control (p=0.02) at 15 min, whilst it increased signifi-
cantly at 60 min (p<0.01). A higher dose (2 mg/kg) of
haloperidol did not elicit any changes in the activity
of PP2A. Collateral assays performed in the presence of
OA, a PP2A inhibitor, resulted in the total abolition
of phosphatase activity. Although OA also inhibits
PP1, the substrate used for phosphatase assay,
RRA(pT)VA, is a poor substrate for PP1. Thus, it was
confirmed that the phosphatase activity emanated
from the OA-sensitive PP2A (Figure 2).
To demonstrate the involvement of PP2A in the
MEK-ERK pathway after haloperidol treatment more
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directly, we next investigated whether these molecules
are co-precipitated, and if so, whether haloperidol
treatment affects the binding. The dephosphorylating
activity of PP2A requires a physical interaction with
the substrate molecule (Sontag, 2001). Protein samples
collected 60 min after 0.5 or 2 mg/kg haloperidol
were immunoprecipitated with antibodies against
Raf-1, MEK1/2, or ERK1/2, and then immunoblotted
with antibodies against PP2A, Raf-1, MEK1/2, or
ERK1/2. The binding of PP2A to MEK1/2 increased
under the low-dose condition (0.5 mg/kg) compared
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Figure 1. Dose- and time-dependent changes in the phosphorylation levels of Raf-1, MEK1/2, ERK1/2, and p90RSK in the rat
frontal cortex after haloperidol (Hal) treatment. The immunoreactivity of p-Ser217/221-MEK1/2, p-Thr202/Tyr204-ERK1/2,
and p-Thr360/Ser364-p90RSKwas elevated at 15 min and decreased from 30 min to 120 min after treatment with 0.5 or 1 mg/kg
haloperidol. Haloperidol (2 and 4 mg/kg) did not induce significant changes. The immunoreactivity of p-Ser338-Raf-1 and
p-Ser259-Raf-1 did not change under any conditions examined. (a) Representative immunoblots of the rat frontal cortex
15, 30, 60, and 120 min after haloperidol treatment for the indicated doses. V indicates the vehicle-treated control.
(b) Quantification of the immunoblot data using a densitometric analysis of band intensity. Data are expressed as the relative
optical density (OD) and given as the average values and standard errors (n=4 for each treatment group). The relative ODs
are percentages of the OD of each vehicle control. The asterisks (*) indicate statistically significant differences in each
immunoreactivity value compared to the vehicle control (p<0.05).
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change under the high-dose condition (2 mg/kg).
The binding of PP2A to ERK1/2 showed the same
pattern. However, the binding of PP2A to Raf-1 did
not change significantly under either low-dose
(0.5 mg/kg) and high-dose (2 mg/kg) conditions. The
immunoreactivity of PP2A in the original lysate used
for the immunoprecipitation analysis did not change
(Fig. 3).
In addition, Raf-1 kinase activity was examined to
determine whether the changes in the phosphor-
ylation of MEK1/2 and ERK1/2 are related to Raf-1
activity. As expected by the finding of no changes
in immunoreactivities of p-Ser338-Raf-1 and p-Ser259-
Raf-1, Raf-1 kinase activity did not alter significantly at
15 min and 60 min after haloperidol (0.5 and 2 mg/kg)
treatment (Fig. 4).
Discussion
Haloperidol (0.5 and 1 mg/kg), induced biphasic
changes in the phosphorylation level of MEK-ERK-
p90RSK and in the activity of PP2A. At an earlier
time (15 min), the phosphorylation of the kinases was
elevated, with decreased activity of PP2A. At a later
time (60 min), the reverse was observed. At this time,
the binding of PP2A to its potential substrates, MEK
or ERK, also increased. However, higher dosages
of haloperidol (2 and 4 mg/kg) affected neither
the phosphorylation status of MEK-ERK-p90RSK
nor the activity of PP2A. Our findings indicate the
involvement of PP2A in the dose- and time-dependent
changes of MEK-ERK-p90RSK phosphorylation in re-
sponse to haloperidol treatment.
Our results concerning the dose- and time-
dependent effect of haloperidol on the ERK pathway
encompass the previous inconsistent findings. At a
dosage of 0.5 or 1 mg/kg, haloperidol either increased
ERK phosphorylation at 15 min (Valjent et al., 2004) or
decreased ERK phosphorylation in the rat or mouse
frontal cortex at 30 min or 120 min (Fumagalli et al.,
2006 ; Pascoli et al., 2005). These results seemed to
contradict each other. In our experiment, however, we
found that these are not contradictory but instead
sequential effects : an early (15 min) increase and
late (30 min and thereafter) decrease. It can also be
postulated that the dose itself can affect the time-
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Figure 2. Changes in PP2A activity in the rat frontal cortex
after haloperidol treatment. PP2A activity in the rat frontal
cortex was measured 15 min and 60 min after administering
0.5 and 2 mg/kg haloperidol. After injecting 0.5 mg/kg
haloperidol, the PP2A activity was reduced significantly at
15 min and increased significantly at 60 min. No significant
changes in PP2A activity were demonstrated after treatment
with 2 mg/kg haloperidol. The data are the average value
and standard error of each optical density of PP2A activity
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Figure 3. Binding of PP2A to Raf-1, MEK1/2, and ERK1/2 in
the rat frontal cortex after haloperidol treatment.
Immunoprecipitation analysis of PP2A with Raf-1, MEK, and
ERK in the rat frontal cortex after haloperidol (Hal) treatment.
(a) Results shown are representative of five independent
experiments with similar results. Immunoprecipitation (IP)
analysis revealed that the binding of PP2A to MEK1/2 and
ERK1/2, not to Raf-1, was increased significantly 60 min after
the injection of 0.5 mg/kg haloperidol. The immunoreactivity
of PP2A in the lysate used for immunoprecipitation and that
of Raf-1, MEK1/2, or ERK1/2 in the immunoprecipitated
samples did not change. (b) The immunoblot (IB) data
were quantified using densitometry, and the ratios of
immunoreactivity of PP2A to that of Raf-1, MEK1/2, or
ERK1/2 in the immunoprecipitated samples were compared
as described in the legend of Figure 1 (n=5 for each treatment
group). V, Vehicle-treated control.
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lower dose of haloperidol (0.2 mg/kg) increased ERK
phosphorylation until 60 min in the mouse striatum
and prefrontal cortex (Pozzi et al., 2003).
The upstream signalling mechanism regulating
MEK-ERK in response to haloperidol can be explained
by several factors. We examined the kinase regulating
the MEK-ERK pathway, Raf-1. However, phosphor-
ylation and kinase activity of Raf-1, the canonical
upstream kinase of MEK, did not change, suggesting
that regulation at the Raf-1 level does not work
after haloperidol treatment. In addition, according
to Kim et al. (2006), a metabolite of haloperidol,
3-(4-fluorobenzoyl) propionic acid, inhibits MEK
activity via direct binding to MEK. However, this
explanation is unsatisfactory considering the finding
that lower doses of haloperidol reduced the MEK
phosphorylation, whilst higher doses did not.
A transient increase in the phosphorylation of MEK-
ERK-p90RSK followed by a long-lasting decrease
suggests involvement of a dephosphorylating mech-
anism. Therefore, we examined the association of
PP2A with ERK, one of the key regulators of the ERK
pathway (Alessi et al., 1995 ; Sontag, 2001) following
haloperidol treatment. Haloperidol treatment regu-
lated PP2A activity in a dose- and time-dependent
manner. The phosphorylation profiles of its possible
substrates, MEK and ERK, suggested that this change
in PP2A activity could be a regulator of the ERK sig-
nalling system after haloperidol treatment. The level
of MEK-ERK-p90RSK phosphorylation showed the
inverse pattern to PP2A activity level. The increased
PP2A activity observed at a later time when MEK/
ERK phosphorylation decreased was prominent, and,
moreover, was accompanied by an increased physical
association between PP2A and MEK-ERK. However,
the decreased PP2A activity observed at an earlier
time when ERK phosphorylation increased was not
prominent, suggesting the possible involvement of
another mechanism, in addition to regulation via
PP2A, in ERK activation. In addition, the binding of
PP2A to Raf-1 did not change significantly after
haloperidol treatment. Taken together with the finding
of no changes in Raf-1 activity, the regulatory action
of PP2A on the MEK-ERK pathway in response to
haloperidol seems to be independent of Raf.
The time-dependent changes can be related to the
action of haloperidol on dopamine receptors. As
haloperidol initially antagonized the presynaptic
inhibitory D2 autoreceptor, haloperidol treatment in-
duced a rapid and transient increase in dopamine
transmission in the rat brain (Garris et al., 2003 ; Lidsky
and Banerjee, 1993). Under the blockade of the D2
receptor by haloperidol, increased dopamine might
stimulate the D1 receptor, which is responsible for the
ERK activation that occurs in response to doapminer-
gic stimulation (Valjent et al., 2000, 2005 ; Zhang et al.,
2004). However, this initial response to autoreceptor
blockade undergoes rapid tolerance, and a progressive
decrease in dopamine level ensues (Garris et al., 2003;
Imperato and Di Chiara, 1985). This process may be
associated with the biphasic effect of haloperidol
(0.5 and 1 mg/kg) on ERK and PP2A. In addition, the
initial increase of ERK phosphorylation may also be a
consequence of the inihibition of the acute D2 receptor-
Gi protein-mediated inactivation of ERK (Banihashemi
and Albert, 2002 ; Van-Ham et al., 2007). Taken to-
gether, the sequential alterations in dopaminergic
transmission and the combined involvement of the D1
and D2 receptors following haloperidol treatment
may be related to the biphasic changes in ERK phos-
phorylation.
The pharmacological action of haloperidol is
believed to be primarily mediated by D2 receptor
antagonism. However, haloperidol also affects a1-
adrenergic, D1, and 5-HT2 serotonin receptors,
although to a lesser extent (Horacek, 2006 ; Ohta, 1976;
Reimold et al., 2007 ; Schotte et al., 1993). Stimulation
of the D1 or a1-adrenergic receptor activated ERK
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Figure 4. Raf kinase activity in the rat frontal cortex after
haloperidol (Hal) treatment. Raf-1 kinase activity in the rat
frontal cortex was measured 15 min and 60 min after
administering 0.5 and 2 mg/kg haloperidol. (a) Results
shown are representative of five independent experiments
with similar results. The immunoreactivity of p-MEK1/2, a
substrate of Raf-1, did not change after haloperidol treatment.
(b) There were no significant changes in Raf-1 kinase activity.
Quantification of the immunoblot data using a densitometric
analysis of band intensity is as described in the legend to
Figure 1 (n=5 for each treatment group). V, Vehicle-treated
control.
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and Minneman, 1999), and haloperidol blocked D1
receptor-Gs protein-related signalling (Cai et al., 1999 ;
Cussac et al., 2004) and affected a1-adrenoreceptor-
coupled signals in a dose-dependent manner (Borda
et al., 1999 ; Nalepa, 1993). In addition, serotonerginc
modulation also affected ERK activity (Beaulieu et al.,
2006 ; Johnson-Farley et al., 2005 ; Quinn et al., 2002).
The receptor occupancy profile of haloperidol is dose-
dependent (Schotte et al., 1993), and this complex effect
on neurotransmitter receptors may contribute to the
dose-dependent effect of haloperidol on intracellular
signalling alterations, a process that needs further
clarification.
PP2A has been reported to play an important role
in dopamine receptor signalling. PP2A regulates D2
class-receptor-mediated Akt phosphorylation through
the formation of a signalling complex with b-arrestin
(Beaulieu et al., 2005). b-arrestin also acts as a scaffold
linking the G-protein coupled receptors (GPCRs), such
as b-adrenergic or angiotensin receptors, and the ERK
pathway (Ahn et al., 2004 ; Shenoy et al., 2006), and
thus the possible linking between the dopamine re-
ceptor, anotherGPCR, andERK through b-arrestinwas
suggested (Bibb, 2005). Therefore, it seems valuable to
study whether b-arrestin is involved in the effect of
haloperidol on the ERK pathway via PP2A. In ad-
dition, PP2A is also involved in the phosphorylation-
mediated regulation of the dopamine transporter,
which modulates the dopamine neurotransmission
system (Vaughan, 2004). Accordingly, PP2A can
regulate dopamine receptor signalling. Despite the
important roles of PP2A in the dopamine neuro-
transmission system, the effect of antipsychotics on
PP2A remains to be clarified.
Previously, we reported the acute regulation of
PP2A activity after electroconvulsive seizure, another
psychotropic treatment modality (Kang et al., 2005).
Together with our present finding, PP2A might be a
valuable target for clarifying the acute intracellular
action of antipsychotic treatment. There are only a few
reports concerning the chronic effect of antipsychotics
on PP2A. The down-regulation of protein serine/
threonine phosphatase in the rat frontal cortex
(MacDonald et al., 2005) or reductions in calcineurin
A expression without changes in PP2A expression in
the rat striatum and prefrontal cortex (Rushlow et al.,
2005) after chronic antipsychotic treatment, including
haloperidol, has been reported. However, acute regu-
lation differs from the chronic response, and further
investigations are necessary to understand the role of
PP2A in the action mechanism of antipsychotics.
Taken together, PP2A might be a key regulator
of the MEK-ERK-p90RSK pathway in response to
haloperidol treatment, but further studies are required
to clarify the detailed molecular mechanism by which
haloperidol regulates PP2A activity. Our finding
concerning the acute effect of haloperidol on PP2A
should increase understanding of the possible in-
volvement of a dephosphorylating mechanism in the
acute action of antipsychotics.
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